Disease · MONDO_0002367

kidney cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kidney cancer. Diseases, record MONDO_0002367. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002367

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kidney cancer; Open Targets
Open Targets ID: MONDO_0002367; Open Targets
Other names: cancer of kidney, malignant kidney neoplasm, malignant kidney tumor, malignant kidney tumour, malignant neoplasm of kidney, malignant neoplasm of the kidney, malignant renal neoplasm, malignant renal tumor, malignant renal tumour, malignant tumor of kidney, malignant tumor of the kidney, malignant tumour of the kidney; Open Targets
Disease Ontology: DOID:263; Disease Ontology
MeSH: D007680; MeSH
NCI Thesaurus: C7548; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 17 of its 108 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs108

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 3	ClinicalTrials.gov and TTD	12	11	11	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
SUNITINIB MALATE	CHEMBL1567	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 108

See all 108 drugs

Targets186

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	10	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	9	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
PDCD1	Programmed cell death protein 1	6	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	5	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 3	https://conductscience.org/library/genes/2322	Drugs and targets
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	4	Macrophage colony stimulating factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1436	Drugs and targets

1 to 10 of 186

See all 186 targets

Trials114

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02811861	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma	Phase 3	1,069	2021-09-24	Renal Cell Carcinoma	EVEROLIMUS, LENVATINIB, PEMBROLIZUMAB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00375674	A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer	Phase 3	674	2017-08-18	Kidney Neoplasms	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT00378703	Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer	Phase 2	361	2015-05-05	Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7	BEVACIZUMAB, SORAFENIB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00303719	Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy	Phase 2	342	2020-05-12	Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes	CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE, MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT01835158	Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer	Phase 2	157	2018-12-21	Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7	CABOZANTINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02761057	Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed	Phase 2	152	2022-09-02	Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma	CABOZANTINIB, CRIZOTINIB, SAVOLITINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00618982	Sorafenib Dose Escalation in Renal Cell Carcinoma	Phase 2	83	2010-05-27	Carcinoma, Renal Cell	SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00126503	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	Phase 1/2	73	2013-06-28	Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer	BEVACIZUMAB, SORAFENIB TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT01727089	Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	Phase 2	59	2018-06-26	Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma	BEVACIZUMAB, CAROTUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT05014828	To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors	Phase 2	58	2025-08-24	Advanced Solid Tumor	LENVATINIB, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 114

See all 114 trials

Comparisons in its trials33

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sunitinib vs Placebo: deaths from any cause	67 of 306	76 of 304	610	NCT00375674	Trial comparisons
Sunitinib vs Placebo: serious adverse events	67 of 306	52 of 304	610	NCT00375674	Trial comparisons
High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease	2 of 13	79 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Serious Adverse Events	0 of 13	47 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Overall Survival	8 of 13	181 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Transplant Related Mortality	2 of 13	40 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: deaths from any cause	6 of 13	124 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: Neutrophil and Donor Cell Engraftment	12 of 13	289 of 292	305	NCT00303719	Trial comparisons
High Risk Patients vs Standard Risk Patients: serious adverse events	1 of 13	53 of 292	305	NCT00303719	Trial comparisons
Arm I (Cabozantinib-s-malate) vs Arm II (Sunitinib Malate): serious adverse events	39 of 78	39 of 72	150	NCT01835158	Trial comparisons

1 to 10 of 33

See all 33 comparisons in its trials

Papers from its trials75

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31894292	RESULT	1	PubMed
31882719	RESULT	1	PubMed
31831767	RESULT	1	PubMed
31533931	RESULT	1	PubMed
31101621	RESULT	1	PubMed
30975030	RESULT	1	PubMed
30405781	RESULT	1	PubMed
30220708	RESULT	1	PubMed
29846250	RESULT	1	PubMed
29632736	RESULT	1	PubMed

1 to 10 of 75

See all 75 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002367

GET https://conductscience.org/api/diseases/v1/MONDO_0002367/drugs?page=2

API reference For AI assistants